- Home
- NGNE vs KLTR Comparison
NGNE vs KLTR Comparison
Compare NGNE & KLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- KLTR
- Stock Information
- Founded
- NGNE 2003
- KLTR 2006
- Country
- NGNE United States
- KLTR United States
- Employees
- NGNE N/A
- KLTR N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- KLTR EDP Services
- Sector
- NGNE Health Care
- KLTR Technology
- Exchange
- NGNE Nasdaq
- KLTR Nasdaq
- Market Cap
- NGNE 325.3M
- KLTR 302.6M
- IPO Year
- NGNE N/A
- KLTR 2021
- Fundamental
- Price
- NGNE $18.48
- KLTR $1.63
- Analyst Decision
- NGNE Strong Buy
- KLTR Buy
- Analyst Count
- NGNE 7
- KLTR 3
- Target Price
- NGNE $41.86
- KLTR $2.83
- AVG Volume (30 Days)
- NGNE 110.1K
- KLTR 277.5K
- Earning Date
- NGNE 08-11-2025
- KLTR 08-07-2025
- Dividend Yield
- NGNE N/A
- KLTR N/A
- EPS Growth
- NGNE N/A
- KLTR N/A
- EPS
- NGNE N/A
- KLTR N/A
- Revenue
- NGNE N/A
- KLTR $181,350,000.00
- Revenue This Year
- NGNE N/A
- KLTR $3.43
- Revenue Next Year
- NGNE N/A
- KLTR $2.96
- P/E Ratio
- NGNE N/A
- KLTR N/A
- Revenue Growth
- NGNE N/A
- KLTR 2.56
- 52 Week Low
- NGNE $6.88
- KLTR $1.06
- 52 Week High
- NGNE $74.49
- KLTR $2.82
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- KLTR 48.46
- Support Level
- NGNE $19.59
- KLTR $1.38
- Resistance Level
- NGNE $20.46
- KLTR $1.66
- Average True Range (ATR)
- NGNE 1.23
- KLTR 0.09
- MACD
- NGNE -0.20
- KLTR 0.02
- Stochastic Oscillator
- NGNE 13.37
- KLTR 85.71
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.